FDA Warns Against Use Of Needle-Free Devices With Dermal Fillers
Executive Summary
The agency’s warning says that needle-free dermal filler “pens” sold on social media could pose a serious risk to consumers.
You may also be interested in...
US FDA Panel Grapples With Dermal Filler Adverse Events
Physicians on the panel backed suggestions including improved labeling, broadening the patient pool for clinical trials, and more thoroughly tracking adverse events.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.